NEURONES |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.4 EUR | +0.53% |
|
+0.85% | +8.34% |
| May. 29 | Neurones: Invesco Ltd falls below 5% of share capital | CF |
| May. 15 | Neurones: 9.5% sales growth in Q1 | CF |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: IT Services & Consulting
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +8.34% | 1.25B | - | ||
| -19.53% | 177B | A- | ||
| -3.23% | 159B | B+ | ||
| +2.05% | 153B | B- | ||
| +5.13% | 100B | A- | ||
| +9.84% | 81.11B | A- | ||
| +22.85% | 75.87B | C- | ||
| -8.81% | 69.81B | A | ||
| -31.57% | 45.63B | C | ||
| -9.69% | 42.96B | A- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- NRO Stock
- Ratings NEURONES
